Nektar Therapeutics is a biopharmaceutical company that applies polymer chemistry and related drug-delivery science to design new medicines, historically including PEGylation approaches. Its development focus has centered on immunology and immuno-oncology candidates intended to modulate immune responses in cancer and other diseases. Revenue is typically limited and tied to partnerships, royalties or early commercial arrangements rather than a large in-house product franchise. The company serves a research and clinical audience of partners, investigators and specialty physicians.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 10.5 | — | -50.9 | — |
| Q2 2025 | 11.2 | — | -41.6 | — |
| Q3 2025 | 11.8 | — | -35.5 | — |
| Q4 2025 | 21.8 | — | -36.1 | — |
| Q1 2026 | 10.9 | 3.8% | -44.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Pharvaris N.V. (PHVS), Hyperliquid Strategies Inc. (PURR), Merchants Bancorp (MBIN), Payoneer Global Inc. (PAYO), Uniti Group Inc. (UNIT), Evolution Metals & Technologies Corp. (EMAT)